A Randomized, Double Blind, Comparative, Phase I Study To Evaluate The Safety, Tolerability And Immunogenicity Of Three Formulations (15µg Without Adjuvant, 7.5µg With Adjuvant And 3.75µg With Adjuvant) Of Monovalent H1N1 Influenza A (2009) Virus Vaccine In Healthy Adults. - H1N1Adults

Trial Profile

A Randomized, Double Blind, Comparative, Phase I Study To Evaluate The Safety, Tolerability And Immunogenicity Of Three Formulations (15µg Without Adjuvant, 7.5µg With Adjuvant And 3.75µg With Adjuvant) Of Monovalent H1N1 Influenza A (2009) Virus Vaccine In Healthy Adults. - H1N1Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top